{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:31:21Z","timestamp":1789392681673,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Resource Services Administration"},{"DOI":"10.13039\/100000038","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In the EVEREST trial, tolvaptan improved symptoms and body weight during hospitalization for heart failure (HF), but did not improve post-discharge cardiovascular outcomes. We hypothesized that this disconnect between the short- and long-term effects may be related to changes in serum osmolality. We describe the longitudinal profile of osmolality and its response to tolvaptan during and after hospitalization for HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>EVEREST enrolled 4133 patients hospitalized for HF and reduced EF. Serum osmolality data were available in 3744 (91%). We assessed the effects of tolvaptan on serum osmolality and related these effects to in-hospital changes in body weight and physician-assessed symptoms. Calculated values of osmolality, determined from serum sodium, blood urea nitrogen, and glucose, were 3\u20134 mOsm\/kg higher than concurrently measured serum osmolality at enrolment and discharge in both treatment arms. During hospitalization in the placebo group, serum osmolality slightly increased throughout hospitalization, whereas serum sodium decreased and blood urea nitrogen increased until discharge. Tolvaptan increased osmolality by hospital day 1, but this effect diminished by post-discharge week 4\u20138 and disappeared by post-discharge week 56. In-hospital changes in osmolality were poorly correlated with in-hospital changes in body weight and physician-assessed dyspnoea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tolvaptan increased serum osmolality during hospitalization for HF, a time frame when the drug also improved signs and symptoms of HF. However, this effect on osmolality declined in the early post-discharge period, when tolvaptan failed to influence clinical outcomes. Serum osmolality, which can be estimated based on readily available laboratory parameters, may be a marker or a target of response to tolvaptan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.415","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T02:18:44Z","timestamp":1444184324000},"page":"185-191","source":"Crossref","is-referenced-by-count":16,"title":["Contrasting Acute and Chronic Effects of Tolvaptan on Serum Osmolality in the EVEREST Trial"],"prefix":"10.1093","volume":"18","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart & Vascular Center and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldsmith","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hennepin County Medical Center, University of Minnesota , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Dipartimento Cardiovascolare, Azienda Ospedaliera Papa Giovannni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"2026011721135957800_ejhf415-bib-0001","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011721135957800_ejhf415-bib-0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.74","article-title":"Decongestion in acute heart failure","volume":"16","author":"Mentz","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721135957800_ejhf415-bib-0003","first-page":"R660","article-title":"Reflex control of osmotically stimulated vasopressin in normal humans","volume":"248","author":"Goldsmith","year":"1985","journal-title":"Am J Physiol"},{"key":"2026011721135957800_ejhf415-bib-0004","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721135957800_ejhf415-bib-0005","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"2026011721135957800_ejhf415-bib-0006","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026011721135957800_ejhf415-bib-0007","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/eurheartj\/ehp144","article-title":"Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial","volume":"30","author":"Blair","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011721135957800_ejhf415-bib-0008","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J Card Fail"},{"key":"2026011721135957800_ejhf415-bib-0009","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2011.02.027","article-title":"Effects of tolvaptan on physician assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials","volume":"161","author":"Pang","year":"2011","journal-title":"Am Heart J"},{"key":"2026011721135957800_ejhf415-bib-0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721135957800_ejhf415-bib-0011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1067\/mem.2001.119455","article-title":"Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap","volume":"38","author":"Purssell","year":"2001","journal-title":"Ann Emerg Med"},{"key":"2026011721135957800_ejhf415-bib-0012","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"2026011721135957800_ejhf415-bib-0013","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/eurheartj\/ehr238","article-title":"Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial","volume":"32","author":"Blair","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011721135957800_ejhf415-bib-0014","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jacc.2012.11.054","article-title":"Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort","volume":"61","author":"Mebazaa","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135957800_ejhf415-bib-0015","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135957800_ejhf415-bib-0016","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/eurjhf\/hfr150","article-title":"Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial","volume":"13","author":"Pitt","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011721135957800_ejhf415-bib-0017","doi-asserted-by":"crossref","first-page":"F1080","DOI":"10.1152\/ajprenal.00052.2012","article-title":"Vasopressin V1a receptor is required for nucleocytoplasmic transport of mineralocorticoid receptor","volume":"303","author":"Hori","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026011721135957800_ejhf415-bib-0018","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1681\/ASN.2010050468","article-title":"Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid\u2013base homeostasis","volume":"22","author":"Izumi","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026011721135957800_ejhf415-bib-0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2013.09.032","article-title":"Increased vasopressin 1A receptor expression in failing human hearts","volume":"63","author":"Zhu","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/2\/185\/66380161\/eurjhf_18_2_185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/2\/185\/66380161\/eurjhf_18_2_185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:14:23Z","timestamp":1768702463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/2\/185\/8423185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,10,7]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.415","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2015,10,7]]}}}